If you're looking for a smart stock to buy right now, look no further than Celgene (NASDAQ: CELG). The big biotech has hit a rough patch lately, with a major clinical setback, missing third-quarter revenue expectations, and lowering its full …
He runs a stock-only portfolio that acts more like a balanced fund ... Instead of …
JUNO stock generated over 31.8% returns in the last four weeks ... Moreover, the revenue recognized under their Celgene Collaboration Agreement and Celgene CD19 License improved against the prior year period. Juno also controlled their …
Over the last six months, Vertex was up 27.2% while Celgene was down 16.9% …
Celgene turned in a brutal third-quarter earnings report, missing revenue forecasts and cutting its long-term profit outlook. Traders were woefully unhedged by several measures, leaving them vulnerable to feel the brunt of the stock's 20% drop. …
Celgene Corporation (CELG) is not your typical biotech stock. While the stock market has been choppy for the last few months and many risk-on plays in biotechnology have seen plenty of volatility, CELG stock has been marching steadily …
Celgene Corporation (NASDAQ: CELG) is a biopharmaceutical company that researches and develops drugs for treating inflammatory diseases and various types of cancer. Celgene's core drugs are Revlimid, which makes up 66% of sales, …
Even some of the biggest and best have things go wrong every now and then. Celgene (NASDAQ: CELG) has been the best-performing biotech stock over the last five years among big biotechs with market caps over $50 billion. And now, …
Celgene (NASDAQ: CELG) stock has been in my investment portfolio since 2013. I enjoyed a couple of great years with the biotech stock performing really well. Over the past couple of years, however, Celgene hasn't generated high …